Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of the literature

Du,Juan; Qian,Xiaoping; Liu,Baorui

doi:10.3892/ol.2012.974

Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of the literature

Authors:
- Juan Du
- Xiaoping Qian
- Baorui Liu
View Affiliations

Affiliations: The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing 210008, P.R. China
Published online on: October 17, 2012 https://doi.org/10.3892/ol.2012.974
Pages: 381-385

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. Prognosis and treatment options are stage-dependent. Typically, prognosis of patients with unresectable HCC is poor, particularly for patients with distant metastasis. Sorafenib has demonstrated an overall survival benefit and has become the new standard of care for advanced HCC. However, in metastatic HCC, long-term progression-free survival for five years with reduced doses of sorafenib is extremely rare. In clinical practice, certain patients are discontinuing the use of this drug due to its side-effects. We highlight the importance of prolonged sorafenib administration, even at reduced doses. We describe an unusual case of a 74‑year‑old patient with HCC metastatic to the vertebrae that responded to a reduced dose of sorafenib and has subsequently demonstrated no signs of disease progression since starting treatment almost five years ago. This suggests that certain patients with highly progressive HCC involving bone metastasis may achieve long-term survival by reduced doses of sorafenib.

View Figures

View References

1	Bosch FX, Ribes J, Cléries R, et al: Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 9:191–211. 2005. View Article : Google Scholar : PubMed/NCBI
2	Llovet JM and Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 48(Suppl 1): S20–37. 2008. View Article : Google Scholar : PubMed/NCBI
3	Gish RG, Porta C, Lazar L, et al: Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 25:3069–3075. 2007. View Article : Google Scholar : PubMed/NCBI
4	Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
5	Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
6	Yoshida T, Hisamoto T, Akiba J, et al: Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene. 25:6056–6066. 2006. View Article : Google Scholar : PubMed/NCBI
7	Huitzel-Melendez FD, Saltz LB, Song J, et al: Retrospective analysis of outcome in hepatocellular carcinoma (HCC) patients with hepatitis C (C+) versus B (B+) treated with sorafenib (abstract). In: Presented at the 2007 ASCO Gastrointestinal Cancers Symposium. (abstract 173); Orlando, FL. 2007;
8	Zhu AX: Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? BMC Med. 7:422009. View Article : Google Scholar : PubMed/NCBI
9	Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 23:965–972. 2005. View Article : Google Scholar
10	Petrelli A and Giordano S: From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem. 15:422–432. 2008. View Article : Google Scholar : PubMed/NCBI
11	Abbadessa G, Rimassa L, Pressiani T, et al: Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. World J Gastroenterol. 17:2450–2453. 2011. View Article : Google Scholar : PubMed/NCBI
12	Edeline J, Boucher E, Rolland Y, et al: Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 118:147–156. 2012. View Article : Google Scholar
13	Milano A, Perri F, Ciarmiello A, et al: Targeted-therapy and imaging response: a new paradigm for clinical evaluation? Rev Recent Clin Trials. 6:259–265. 2011. View Article : Google Scholar : PubMed/NCBI
14	Horger M, Lauer UM, Schraml C, et al: Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer. 9:208–209. 2009. View Article : Google Scholar